eprintid: 23052
rev_number: 24
userid: 1419
dir: disk0/00/02/30/52
datestamp: 2014-09-23 14:48:49
lastmod: 2021-06-25 01:55:09
status_changed: 2014-09-23 14:48:49
type: article
metadata_visibility: show
item_issues_count: 0
eprint_status: archive
creators_name: Epperly, MW
creators_name: Franicola, D
creators_name: Shields, D
creators_name: Rwigema, JC
creators_name: Stone, B
creators_name: Zhang, X
creators_name: Mcbride, W
creators_name: Georges, G
creators_name: Wipf, P
creators_name: Greenberger, JS
creators_email: 
creators_email: 
creators_email: 
creators_email: 
creators_email: 
creators_email: xichen@pitt.edu
creators_email: 
creators_email: 
creators_email: pwipf@pitt.edu
creators_email: joelg@pitt.edu
creators_id: 
creators_id: 
creators_id: 
creators_id: 
creators_id: 
creators_id: XICHEN
creators_id: 
creators_id: 
creators_id: PWIPF
creators_id: JOELG
title: Screening of antimicrobial agents for in vitro radiation protection and mitigation capacity, including those used in supportive care regimens for bone marrow transplant recipients
ispublished: pub
divisions: sch_as_chemistry
full_text_status: public
abstract: Antibiotic and antifungal agents used in supportive care regimens for bone marrow transplantation recipients contribute to a significant dose-modifying effect of otherwise lethal total body irradiation. To determine whether drugs used in supportive care and other commonly used antibiotics such as tetracycline function as radiation protectors or damage mitigators in vitro, 13 drugs were tested for radiation protection and radiation damage mitigation of 32D cl 3 hematopoietic progenitor cells in clonagenic survival curves in vitro. Antibiotic/Antifungal agents including cilastatin, amikacin, ceftazidine, vancomycin, tetracycline, doxycycline, ciprofloxacin, metronidazole, methacycline, minocycline, meclocycline, Oxytetracycline and rolitetracycline were added in 1, 10, or 100 micromolar concentrations to murine interleukin-3-dependent hematopoietic progenitor cell line 32D cl 3 cells either before or after irradiation of 0 to 8 Gy. Control irradiated 32D cl 3 cells showed radiosensitivity comparable to freshly explanted mouse marrow hematopoietic progenitor cells (D0 1.1 ±0.1 Gy, Ñ 15±0.4). Positive control GS-nitroxide JP4-039 (known radiation mitigator) treated 32D cl 3 cells were radioresistant (D0 1.2±0.1, Ñ 5.8±2.4 (p=0.009)). Of the 13 drugs tested, tetracycline was found to be a significant radiation mitigator (D0 0.9±0.1, Ñ 13.9±0.4 (p=0.0027)). Thus, the radiation dose-modifying effect of some antibiotics, but not those currently used in the supportive care (antibiotic/antifungal regimens) for marrow transplant patients, may act as radiation damage mitigators for hematopoietic cells as well as decreasing the growth and inflammatory response to microbial pathogens.
date: 2010-01-01
date_type: published
publication: In Vivo
volume: 24
number: 1
pagerange: 9 - 19
refereed: TRUE
issn: 0258-851X
other_id: NLM NIHMS269606
other_id: NLM PMC3039923
pmcid: PMC3039923
pmid: 20133970
mesh_headings: Animals
mesh_headings: Anti-Bacterial Agents--pharmacology
mesh_headings: Antifungal Agents--pharmacology
mesh_headings: Bone Marrow Transplantation
mesh_headings: Cell Line
mesh_headings: Cell Survival--drug effects
mesh_headings: Cell Survival--radiation effects
mesh_headings: Dose-Response Relationship, Radiation
mesh_headings: Hematopoietic Stem Cells--drug effects
mesh_headings: Hematopoietic Stem Cells--pathology
mesh_headings: Hematopoietic Stem Cells--radiation effects
mesh_headings: Mice
mesh_headings: Radiation Injuries, Experimental--pathology
mesh_headings: Radiation Injuries, Experimental--prevention & control
mesh_headings: Radiation-Protective Agents--pharmacology
chemical_names: Anti-Bacterial Agents
chemical_names: Antifungal Agents
chemical_names: Radiation-Protective Agents
citation:   Epperly, MW and Franicola, D and Shields, D and Rwigema, JC and Stone, B and Zhang, X and Mcbride, W and Georges, G and Wipf, P and Greenberger, JS  (2010) Screening of antimicrobial agents for in vitro radiation protection and mitigation capacity, including those used in supportive care regimens for bone marrow transplant recipients.  In Vivo, 24 (1).  9 - 19.  ISSN 0258-851X     
document_url: http://d-scholarship-dev.library.pitt.edu/23052/1/licence.txt